High frequency of the 23S rRNA A2058G mutation of *Treponema pallidum* in Shanghai is associated with a current strategy for the treatment of syphilis

Haikong Lu*, Kang Li*, Weimin Gong, Limeng Yan, Xin Gu, Ze Chai, Zhifang Guan and Pingyu Zhou

The preferred drugs for the treatment of syphilis, benzathine and procaine penicillin, have not been available in Shanghai for many years, and currently, the incidence of syphilis is increasing. Alternative antibiotics for patients with syphilis during the benzathine and procaine penicillin shortage include macrolides. The failure of macrolide treatment in syphilis patients has been reported in Shanghai, but the reason for this treatment failure remains unclear. We used polymerase chain reaction technology to detect a 23S rRNA A2058G mutation in *Treponema pallidum* in 109 specimens from syphilis patients. The use of azithromycin/erythromycin in the syphilis patients and the physicians’ prescription habits were also assessed based on two questionnaires regarding the use of macrolides. A total of 104 specimens (95.4%) were positive for the A2058G mutation in both copies of the 23S rRNA gene, indicating macrolide resistance. A questionnaire provided to 122 dermatologists showed that during the penicillin shortage, they prescribed erythromycin and azithromycin for 8.24 ± 13.95% and 3.21 ± 6.37% of their patients, respectively, and in the case of penicillin allergy, erythromycin and azithromycin were prescribed 15.24 ± 22.89% and 7.23 ± 16.60% of the time, respectively. A second questionnaire provided to the syphilis patients showed that 150 (33.7%), 106 (23.8%) and 34 (7.6%) individuals had used azithromycin, erythromycin or both, respectively, although the majority did not use the drugs for syphilis treatment. Our findings suggest that macrolide resistance in *Treponema pallidum* is widespread in Shanghai. More than half of the syphilis patients had a history of macrolide use for other treatment purposes, which may have led to the high prevalence of macrolide resistance. Physicians in China are advised to not use azithromycin for early syphilis.

Emerging Microbes and Infections (2015) 4, e10; doi:10.1038/emi.2015.10; published online 11 February 2015

Keywords: macrolide resistance; *Treponema pallidum*; gene mutation; syphilis

INTRODUCTION

Syphilis has increased rapidly in China in the last decade. In 2013, 444 952 cases were reported, with an incidence of 32.86 cases per 100 000 individuals.1 Shanghai is among the areas with the highest reported incidence, and from 2003 to 2013, 153 716 syphilis cases were presented, of which more than half of the patients (77 931 cases) were with high contagious primary or secondary syphilis (35 804 and 42 127 cases, respectively, provided by the Shanghai Center for Disease Control and Prevention (CDC).

*Treponema pallidum* is the limited-cultivable agent of syphilis. Penicillin has remained the preferred drug for the treatment of syphilis in almost all countries since its discovery more than 60 years ago. Alternative antibiotics that are used during a penicillin shortage or for penicillin-allergic patients with syphilis include doxycycline, tetracycline, ceftriaxone or erythromycin, and more recently, azithromycin.2–4

However, erythromycin and azithromycin treatment failures have been documented in patients with primary and secondary syphilis and in infants with congenital syphilis.3–7 Molecular analysis of the SS14 strain isolated from the clinical specimens of these patients revealed the presence of an adenine (A)-to-guanine (G) transition at the position cognate to A2058 in the *Escherichia coli* 23S rRNA gene compared with the macrolide-sensitive wild-type Nichols strain of *T. pallidum*.8–10 We and other researchers previously reported the failures of azithromycin in preventing congenital syphilis and maternal syphilis and in treating a substantial number of patients with primary or secondary syphilis in Shanghai.5–7

Given the high incidence of contagious primary and secondary syphilis in Shanghai and the treatment failures that have occurred, surveillance of the drug resistance in syphilis in Shanghai is urgently needed. This study aimed to conduct a survey of the use of macrolides by the patients themselves and the drug preference of physicians for syphilis and non-syphilis treatment and its association with the prevalence of macrolide drug resistance in Shanghai.

MATERIALS AND METHODS

Patients

We identified patients with primary or secondary syphilis lesions at the Sexually Transmitted Diseases (STD) Institute at Shanghai Skin Disease Hospital during the period from October 2007–October 2009. Primary syphilis was defined as a clinically compatible case characterized by one or more chancres and inguinal lymphadenopathy and a laboratory confirmation of *T. pallidum* spirochetes in a dark-field
microscopy examination of a lesion or verification via reactive non-treponemal rapid plasma regain (RPR), or toluidine red unheated serum test (TRUST) and treponemal pallidum hemagglutination (TPHA), or T. Pallidum particle agglutination (TPPA). Secondary syphilis was defined as a clinically compatible case characterized by a maculopapular rash and in many cases, lymphadenopathy, and a laboratory test showing a reactive RPR, or TRUST and TPHA or TPPA.

**DNA preparation**
After obtaining written informed consent from the subjects, swab samples were collected from the primary or secondary syphilis lesions, placed directly into vials containing 500 μL of lysis buffer (10 mM Tris, pH 8.0; 0.1 M ethylenediaminetetraacetic acid (EDTA), and 0.5% sodium dodecyl sulfate) and frozen at −20 °C. Genomic DNA was extracted from all of the samples using the DNeasy Tissue Kit (Qiagen, Hilden, Germany) according to the protocols recommended by the manufacturer.

**Polymerase chain reaction (PCR)-based Sanger sequencing**
To detect the 23S rRNA A2058G gene mutation in the swab samples, a PCR-based restriction digestion was performed as previously described. The PCR primers (Table 1) were designed based on the published Nichols strain of the T. pallidum genome. PCR amplification of the 23S rDNA gene was performed for the 628-bp amplicon containing the mutation, followed by MboII (New England Biolabs) digestion of the purified PCR products. The digestion products were separated on 1.5% agarose gels to identify the mutation. By digesting the DNA from SS14 (Street strain 14 of T. pallidum) produces two fragments of 440 bp and 188 bp (Table 1). The wild-type Nichols strain is macrolide-susceptible and does not carry the mutation. To confirm the genotype, the PCR products were purified using a QIAquick PCR Purification Kit (Qiagen, Hilden, Germany), and the DNA sequencing of the purified PCR products was performed on an ABI PRISM 377-96 DNA sequencer (Applied Biosystems Inc., Foster, CA, USA).

To ensure that the DNA from other bacteria was not being amplified from the swabs and to determine if the mutation was present in one or both of the 23S rRNA genes (rrl1 and rrl2) from T. pallidum, a nested PCR amplification was developed using genes (tp0226 and tp0267) unique to T. pallidum. The primers were designed to span tp0226 and rrl1 or tp0267 and rrl2 (GenBank accession number: NC_010741.1). The two 1593-bp amplicons were then used as templates for the amplification of the 628-bp products of the 23S rRNA gene. The sequencing and restriction digestion were performed as described above.

**Questionnaire for the use of macrolides**
Based on the fact that antibiotic selection may contribute to the increased macrolide resistance in syphilis patients in the United States and the reports of macrolide treatment failures in patients with primary or secondary syphilis and infants with congenital syphilis in China, questionnaires on self macrolide use by the patient and physicians’ macrolide-prescribing habits for alternative syphilis regimens and how macrolides were used for syphilis patients were designed to evaluate if antibiotic selection is one of the contributing factors for the increasing macrolide resistance in syphilis patients in China.

**Results**
During October 2007-October 2009, a total of 605 syphilis patients were asked to complete a questionnaire regarding their history of macrolide use. The questions included the following: (i) do you know about the macrolide antibiotics azithromycin and/or erythromycin? If the answer is yes to question (i), answer the following questions: (ii) have you ever used azithromycin? If yes, what did you use it for? (iii) have you ever used erythromycin? If yes, what did you use it for?

**Statistical analysis**
The risks in those with and without the 23S rRNA mutation were assessed via an odds ratio (OR) with a 95% confidence interval (CI). Student’s t-test was used to analyze the probability of the dermatologists to prescribe erythromycin and azithromycin in cases of penicillin shortage, and a P<0.05 was considered to be significant.

**RESULTS**
The 23S rRNA A2058G mutation in primary and secondary syphilis in Shanghai
During October 2007-October 2009, 182 samples from individuals who were diagnosed with primary or secondary syphilis at two clinics were obtained for molecular analysis, and amplifiable T. pallidum DNA was isolated from 109 patients (59.89%). Among the 109 patients, 82 cases were diagnosed as primary syphilis, while 27 were diagnosed with secondary syphilis. The restriction digestion assay showed that 104 samples contained the A2058G mutation in the 23S rRNA genes (95.4%). Figure 1 shows the restriction fragment length polymorphism analysis of the PCR amplicons from the representative samples, suggesting that T. pallidum in 104 of the patients was resistant to azithromycin, while the remaining five were sensitive. DNA sequencing of the PCR amplicons confirmed the nucleic acid substitution.

**Table 1 The genes, PCR primers, and expected product sizes in the mutation analysis**

| Gene target | Primers | Amplicon size (bp) |
|-------------|---------|--------------------|
| tp47        | F: CGTGTGTATCA ACTATGG R: TCA ACCGTGTACTCAGTC | 310 |
| tp0226      | F: GTACGCGAACACCCAG ACGAC GAG R: GCCCGGAAACCTCTTTTAT | 1593 |
| tp0267      | F: GTACGCGAACACCCAG ACGAC GAG R: GAACGCGTCCCCGAAAACCTCA | 1593 |
| 23S rRNA    | F: GTACGCGAACACCCAG ACGAC GAG R: AGTCAAAAGGCGOCACCTAC | 628 |

Emerging Microbes and Infections
The relationship between the 23S rRNA A2058G mutation and macrolide use

A total of 104 patients were infected with macrolide-resistant T. pallidum; among them, 40 cases had available macrolide use information, of which only eight (20%), six (15%) and one (2.5%) were treated with azithromycin, erythromycin or both, respectively. For the five patients infected with the Nichols strain, two (40%) of the cases with macrolide use information had never used azithromycin or erythromycin. Table 2 shows the socio-demographic characteristics of these patients.

The above analysis suggests that the relatively high-frequency use of macrolides may have led to the macrolide resistance, although an insufficient number of wild-type T. pallidum was obtained in our study because of the widespread macrolide resistance. To further investigate this notion, we surveyed the physicians’ prescription habits using a questionnaire. The results showed that a penicillin allergy was the more important factor for determining the drug selection. In the case of benzathine and procaine shortage, and not an allergy, the majority of the dermatologists chose ceftriaxone (data not shown). Additionally, the majority of the dermatologists did not frequently prescribe erythromycin or azithromycin (Table 3). Using descriptive statistics, the data show that the majority of the physicians tended to prescribe erythromycin rather than azithromycin (P<0.001).

Because the above results did not answer our questions, we conducted an additional survey regarding the azithromycin and erythromycin use in syphilis patients of all stages (i.e., primary, secondary, tertiary and latent syphilis) using a macrolide use questionnaire. Overall, 605 syphilis patients were recruited. Out of 445 patients, 150 (33.7%), 106 (23.8%) and 34 (7.6%) had a therapeutic history of azithromycin, erythromycin or use of both, respectively, whereas for the treatment of syphilis, only 23 (3.8%) used azithromycin and none were prescribed erythromycin.

DISCUSSION

Shortly after the introduction of erythromycin as a form of therapy in the 1950s, resistance to the drug was observed in bacterial pathogens, and several erythromycin-resistant strains were also found to be cross-resistant to all other macrolides. As several clinical trials have demonstrated the successful use of a single dose of azithromycin for early syphilis and the equivalent efficacy of azithromycin and benzathine penicillin G in treating early syphilis in randomized clinical trials, azithromycin is believed to be a more attractive treatment alternative for early syphilis than intramuscular penicillin G because it can be administered orally in a single dose and it is more convenient than standard intramuscular penicillin, especially for those who are allergic to penicillin, when there is a shortage of penicillin or when trained staff and injecting equipments are in short supply. According to the United Kingdom national guidelines on the management of syphilis, azithromycin has been recommended to treat incubating syphilis and for epidemiological treatment (a single, oral 1-g dose).4 However, failures have been observed in syphilis patients treated with macrolide antibiotics5–7,9,19,20.

Although macrolide-resistant T. pallidum is known in China10 and azithromycin treatment failures have been reported in Shanghai,6,7,9 the data regarding the use of macrolide antibiotics for the treatment of syphilis and macrolide-resistant T. pallidum are limited. There are many unanswered questions in China, such as, what is the proportion of macrolide-resistant T. pallidum? What contributes to the occurrence of macrolide-resistant T. pallidum? What percentage of people is routinely treated with macrolide antibiotics? Why were individuals with syphilis given macrolide antibiotics?

According to the China CDC STD treatment guidelines,2 the standard and first choice for syphilis is penicillin, and alternative antibiotics, including erythromycin and azithromycin, are allowed for treating syphilis cases only when penicillin is not available or when the patient is allergic to penicillin. However, since the beginning of 2006, there has been a constant shortage of benzathine penicillin and procaine penicillin in Shanghai, and in most hospitals, these two forms of penicillin have been not available for years. Therefore, the alternative antibiotics for syphilis were used during this period.

In this study, 122 dermatologists from 99 hospitals in Shanghai were recruited and surveyed. Ceftriaxone is the first alternative choice for physicians when penicillin is not available or when the patient is allergic to penicillin (data not shown). The data also showed that the physicians’ macrolide antibiotic prescription habits for syphilis vary, and they do not frequently use macrolide antibiotics for syphilis. This result was not what we expected, and it did not correspond with the high prevalence of macrolide-resistant T. pallidum in Shanghai. However, an investigation of patients with syphilis told us a different story. Among the patients with information regarding their history of macrolide antibiotic use, although only 5.2% were treated with azithromycin for syphilis, 65.1% had used macrolide antibiotics. In China, macrolides have been widely used to treat many pathogenic bacteria, including Chlamydia trachomatis, Ureaplasma urealyticum, the non-gonococcal urethritis (NGU), which is one of the most common sexually infectious diseases in China. Azithromycin is recommended as the first choice for treating NGU according to the China CDC STD treatment guidelines, and is also used as a prophylaxis against Chlamydia infection in individuals with gonorrhea. In China, although all antibiotics are prescription drugs, it is not difficult

Table 2 The socio-demographic characteristics among patients with primary or secondary syphilis (n=109)

| Mutation (104) | Wild type (5) | OR (95% CI) |
|---------------|---------------|-------------|
| Male/female   | 72/32         | 3/2         | 1.5 (0.12, 13.71) |
| Age (average) | 41.1          | 38.6        |                |
| Primary/secondary | 78/26     | 4/1         | 0.75 (0.01, 8.06) |

Table 3 The number of dermatologists who prescribed erythromycin and azithromycin during periods of penicillin shortage

|                      | Erythromycin | Azithromycin |
|----------------------|--------------|--------------|
| Non-pregnant without allergy | 8.24±13.95  | 3.21±6.37    |
| Non-pregnant with allergy | 15.24±22.89 | 7.23±16.60   |
| Pregnant women without allergy | 22.70±33.28 | 3.36±8.29    |
| Pregnant women with allergy | 31.61±38.26 | 5.51±11.89   |
to obtain oral antibiotics without a prescription from a pharmacy for all types of bacterial infections. It is worth noting that 24.8% and 17.5% of the patients had a history of azithromycin and/or erythromycin treatment, whereas only 3.8% and 0%, respectively, were for syphilis. Combining the high percentage of T. pallidum mutants, we suggest that the macrolide-resistant T. pallidum mutation was induced by macrolide pressure that did not result from treating syphilis, but rather, from the abuse of macrolides for other infections. It is believed that antibiotic selection may have contributed to the increased macrolide resistance in the United States. In the current study, only a relatively small percentage of the patients had been treated with azithromycin (20%), erythromycin (15%), or both (2.5%). Additionally, some of the patients with wild-type T. pallidum had never used azithromycin or erythromycin. More importantly, all five samples containing the wild-type strain were collected in 2007 and at the beginning of 2008, which was a year after the beginning of the penicillin shortage in Shanghai. After that time, all of the clinically obtained T. pallidum has been macrolide-resistant. Although the results of the macrolide use questionnaire showed that there were no differences between the two groups because of the lack of cases in the wild-type T. pallidum group, it could be interpreted that antibiotic selection may contribute to the increased macrolide resistance in Shanghai. Therefore, syphilis patients who have received macrolide treatment must be closely followed-up with clinical and serological evaluations for treatment efficacy, and if possible, the T. pallidum mutation should be identified or macrolides should not be used for the treatment of syphilis in Shanghai. Currently, the occurrence of macrolide resistance in T. pallidum from other parts of China remains largely undocumented. It is believed that there is a high potential for the occurrence of macrolide-resistant T. pallidum in Nanjing and Guangxi; however, further studies are needed to fully understand the current macrolide use and its association with drug resistance in China.

ACKNOWLEDGEMENTS

The funding for this study was supported in part by grants from the National Natural Science Foundation of China (81371862), the Shanghai Basic Science Foundation (11JC1411600), the Shanghai International Cooperation Project (1343072000), the Shanghai Health Bureau Foundation (20114026), and the Shanghai Hospital Development Center Foundation (SHDC12012237). We greatly appreciate the clinical staff from Shanghai Skin Disease Hospital who recruited the patients and all of participants in this study for their cooperation.

1. Dong GX, Li YX, Teng F et al. [Syphilis in China from 2000 to 2013: epidemiological trends and characteristics.] Chinese Journal of Dermatology 2014; 47: 310–315.
2. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 26–40.
3. Wang QQ, Zhang GC. Guidelines for Diagnosis and Treatment of Sexually Transmitted Diseases. Shanghai: Shanghai Scientific & Technical Publishers, 2007.
4. Kingston M, French P, Goh B. UK National Guidelines on the Management of Syphilis 2008. Int J STD AIDS 2008; 19: 729–740.
5. Centers for Disease Control and Prevention (CDC). Azithromycin treatment failures in syphilis infections–San Francisco, California, 2002–2003. MMWR Morb Mortal Wkly Rep 2004; 53: 197–198.
6. Zhou P, Li K, Lu H et al. Azithromycin treatment failure among primary and secondary syphilis patients in Shanghai. Sex Transm Dis 2010; 37: 726–729.
7. Zhou P, Qian Y, Xu J et al. Occurrence of congenital syphilis after maternal treatment with azithromycin during pregnancy. Sex Transm Dis 2007; 34: 472–474.
8. Fraser CM, Norris SJ, Weinstock GM et al. Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science 1998; 281: 375–388.
9. Katz KA, Klausner JD. Azithromycin resistance in Treponema pallidum. Curr Opin Infect Dis 2008; 21: 83–91.
10. Martin IE, Gu W, Yang Y et al. Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China. Clin Infect Dis 2009; 49: 515–521.
11. Marra CM, Colina AP, Godornes C et al. Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. J Infect Dis 2006; 194: 1771–1773.
12. Lukehart SA, Godornes C, Molini BJ et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004; 351: 154–158.
13. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1267–1272.
14. Weisblum B. Macrolide resistance. Drug Resist Update 1998; 1: 29–41.
15. Kiddugavu MG, Kiwanuka N, Wawer MJ et al. Effectiveness of syphilis treatment using azithromycin and/or benzathine penicillin in Rakai, Uganda. Sex Transm Dis 2005; 32: 1–6.
16. Campos-Outcalt D, Hurwitz S, Mickey T. Use of directly observed azithromycin treatment for syphilis in a homeless woman. Sex Transm Dis 2002; 29: 372.
17. Hook EW 3rd, Martin DH, Stephens J et al. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis 2002; 29: 486–490.
18. Riedner G, Rusiţoţa M, Todd J et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005; 353: 1236–1244.
19. Mitchell SJ, Engelman J, Kent CK et al. Azithromycin-resistant syphilis infection: San Francisco, California, 2000–2004. Clin Infect Dis 2006; 42: 337–345.
20. Stamm LV, Bergen HL. A point mutation associated with bacterial macrolide-resistance is present in both 23S rRNA genes of an erythromycin-resistant Treponema pallidum clinical isolate. Antimicrob Agents Chemother 2000; 44: 806–807.
21. Peng RR, Yin YP, Wei WH et al. Molecular Typing of Treponema pallidum Causing Early Syphilis in China: A Cross-Sectional Study. Sex Transm Dis 2012; 39: 42–45.